Instrument Inactif

Autres langues CSPC Pharmaceutical Group Ltd. Other OTC

Actions

CHJTF

HK1093012172

Produits pharmaceutiques

Autres langues

21/08	Bond Yields, Oil Prices Cap Asian Stock Markets
20/08	Pharma sector doubles down on AI amid hopes of slashing costs, timelines
20/08	CSPC Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026
20/08	CSPC Pharmaceutical's Attributable Profit More Than Doubles in H1; Shares Jump 14%
18/08	CSPC Pharma Unit's Breast Cancer Drug Application Granted Priority Review in China
12/08	CSPC Pharmaceutical Group Limited Provides Update on the Collaboration, Option and License Agreement with Astrazeneca for the Development of siRNA Drugs
12/08	CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus
11/08	CSPC Pharmaceutical Group Limited Initiates Phase I Clinical Trial Of SYS6063 For Treatment Of Relapsed, Refractory Systemic Lupus Erythematosus At First Centre In China
10/08	CSPC Pharmaceutical's Mpox Vaccine Candidate Gets Trial Approval from US FDA
10/08	CSPC Pharmaceutical Group Limited Announces SYS6037 Injection MPOX MRNA Vaccine Obtains Clinical Trial Approval In The U S
05/08	CSPC Pharma Gets $10 Million Milestone Payment from AstraZeneca Under Research Deal
05/08	CSPC Pharma, AstraZeneca Form JV to Build Biologics Manufacturing Facility in China
05/08	CSPC Pharmaceutical Group Limited Announces Receipt of USD 10 Million Milestone Payment Under the Strategic Research Collaboration Agreement with Astrazeneca
05/08	CSPC Pharmaceutical Group Limited And AstraZeneca Enter Into Joint Venture Contract For Establishment Of Joint Venture To Further Deepen Strategic Collaboration
04/08	CSPC Pharma Unit, Alphamab Oncology's Breast Cancer Drug Application Granted Priority Review in China
04/08	CSPC Pharmaceutical Group Limited New Drug Application For Anbenitamab And Docetaxel For Injection (Albumin-Bound) For Neoadjuvant Treatment Accepted By The NMPA
03/08	CSPC Pharma Begins Phase Ib/II Trial of Colorectal Cancer Drug Candidate
03/08	CSPC Pharmaceutical Group Limited Initiates Phase Ib/II Clinical Trial Of SYS6090 Injection For Treatment Of Colorectal Cancer
03/08	CSPC Pharma Wins China Trial Approval for RSV Vaccine
31/07	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYS6041 as Combination Therapy for Treatment of Recurrent Ovarian Cancer At First Centre in China
31/07	CSPC Pharmaceutical Group Limited Announces Recombinant Respiratory Syncytial Virus Vaccine SYS6057 Obtains Clinical Trial Approval In China
30/07	CSPC Pharmaceutical Starts Phase 2 Trial of Hypertension Drug
30/07	CSPC-Licensed Oropharyngeal Cancer Drug Cleared for U.S. Registrational Trial
29/07	CSPC Pharmaceutical Group Limited Announces CRB-701 Receives U.S. FDA Clearance For Registrational Trial For Second-Line Treatment Of Oropharyngeal Cancer
29/07	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYH2062 Injection For Treatment Of Adult Essential Hypertension At First Centre In China